Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
NYSE:BIO
Total Valuation
Bio-Rad Laboratories has a market cap or net worth of $7.80B. The enterprise value is $6.60B.
Market Cap$7.80B
Enterprise Value$6.60B
Share Statistics
Bio-Rad Laboratories has 21,992,308 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,992,308
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bio-Rad Laboratories’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is 2.37%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)2.37%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee333.31K
Profits Per Employee-239.51K
Employee Count7,700
Asset Turnover0.27
Inventory Turnover1.56
Valuation Ratios
The current PE Ratio of Bio-Rad Laboratories is 24.6. Bio-Rad Laboratories’s PEG ratio is ―.
PE Ratio24.6
PS Ratio―
PB Ratio―
Price to Fair Value1.41
Price to FCF―
Price to Operating Cash Flow14.64
PEG Ratio―
Income Statement
In the last 12 months, Bio-Rad Laboratories had revenue of 2.57B and earned -1.84B in profits. Earnings per share was -65.36.
Revenue2.57B
Gross Profit1.38B
Operating Income269.00M
Pretax Income-2.34B
Net Income-1.84B
EBITDA-2.14B
Earnings Per Share (EPS)-65.36
Cash Flow
In the last 12 months, operating cash flow was 534.16M and capital expenditures -186.64M, giving a free cash flow of 347.52M billion.
Operating Cash Flow534.16M
Free Cash Flow347.52M
Free Cash Flow per Share15.80
Dividends & Yields
Bio-Rad Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change-3.53%
50-Day Moving Average256.81
200-Day Moving Average281.50
Relative Strength Index (RSI)71.27
Average Volume (3m)294.05K
Important Dates
Bio-Rad Laboratories upcoming earnings date is Oct 23, 2025, After Close (Confirmed).
Last Earnings DateJul 31, 2025
Next Earnings DateOct 23, 2025
Ex-Dividend Date―
Financial Position
Bio-Rad Laboratories as a current ratio of 6.48, with Debt / Equity ratio of 19.73%
Current Ratio6.48
Quick Ratio4.85
Debt to Market Cap0.13
Net Debt to EBITDA-0.41
Interest Coverage Ratio5.50
Taxes
In the past 12 months, Bio-Rad Laboratories has paid -498.30M in taxes.
Income Tax-498.30M
Effective Tax Rate0.21
Enterprise Valuation
Bio-Rad Laboratories EV to EBITDA ratio is -4.74, with an EV/FCF ratio of 38.15.
EV to Sales3.96
EV to EBITDA-4.74
EV to Free Cash Flow38.15
EV to Operating Cash Flow22.31
Balance Sheet
Bio-Rad Laboratories has $1.37B in cash and marketable securities with $1.41B in debt, giving a net cash position of $32.70M billion.
Cash & Marketable Securities$1.37B
Total Debt$1.41B
Net Cash$32.70M
Net Cash Per Share$1.49
Tangible Book Value Per Share$207.88
Margins
Gross margin is 52.82%, with operating margin of 10.48%, and net profit margin of -71.86%.
Gross Margin52.82%
Operating Margin10.48%
Pretax Margin-91.27%
Net Profit Margin-71.86%
EBITDA Margin-83.46%
EBIT Margin-89.37%
Analyst Forecast
The average price target for Bio-Rad Laboratories is $333.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$333.00
Price Target Upside16.83% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-0.33%
EPS Growth Forecast―